Document is current

Article History

Received: 6 April 2020

Accepted: 1 October 2020

First Online: 25 November 2020

Ethics approval and consent to participate

: The clinical protocol was approved by an independent ethics committee or institutional review board at each participating centre listed in Supplemental Appendix InternalRef removed. All patients provided written informed consent before study entry.

: Not applicable.

: SJ reports personal fees from Actelion, AIRB, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Chiesi, Galecto, Gilead, GlaxoSmithKline, LVL, Mundipharma, Novartis, Pfizer, Roche, and Savara-Serendex. BC reports grants and personal fees from Boehringer Ingelheim and Roche; grants from Apellis and MedImmune; and personal fees from AstraZeneca and Sanofi. RT has received fees or congress invitations from Aguettant, AstraZeneca, Baxter, Braun, Fresenius-Kabi, Lactalis, Nestlé, Nutricia, Roche, Sanofi, Servier, and Shire. ML reports personal fees from AstraZeneca, Boehringer Ingelheim, Fresenius-Kabi, Roche, and Siemens Healthineers. LV reports grants from Boehringer Ingelheim. CV reports personal fees from Boehringer Ingelheim, Hoffmann-La Roche, and Galapagos. MW reports grants and fees paid to her institution from Boehringer Ingelheim and Hoffmann-La Roche; fees paid to her institution from Galapagos and Respivant. MK reports grants and personal fees from Boehringer Ingelheim and Roche. WS and MQ are employees of Boehringer Ingelheim. VC reports research grants, personal fees, and non-financial support from Boehringer Ingelheim; personal fees from AstraZeneca, Bayer/Merck Sharp & Dohme, Celgene, Fibrogen, Galapagos, Galecto, Novartis, Sanofi, and Shionogi; and personal fees and non-financial support from Actelion, and Roche/Promedior.